Lung cancer patients get continued access to promising drug in Safety-Focused Follow-Up study
NCT ID NCT05144997
Summary
This study provides continued access to the lung cancer drug lorlatinib for patients who are already benefiting from it in previous Pfizer trials. It allows 76 participants with specific genetic types of non-small cell lung cancer (ALK-positive or ROS1-positive) to keep receiving treatment while researchers closely monitor long-term safety. The main goal is to better understand the drug's safety profile over extended use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, 100000, China
-
Bhaktivedanta Hospital & Research Institute
Thane, Maharashtra, 401107, India
-
CHU de Rennes - Hôpital Pontchaillou
Rennes, 35033, France
-
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, 210002, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Healthcare Global Enterprises
Bengaluru, Karnataka, 560027, India
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hunan Provincial Tumor Hospital
Changsha, Hunan, 410013, China
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Jilin Cancer Hospital
Changchun, Jilin, 130000, China
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
National University Hospital
Singapore, 119074, Singapore
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
-
Sichuan Cancer hospital
Chengdu, Sichuan, 610041, China
-
Sir Run Shaw Hospital
Hangzhou, Qiantang District, 310016, China
-
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
-
The Second Affiliated Hospital of PLA Air Force Medical University
Xi'an, Shaanxi, 710038, China
-
The Second Affiliated Hospital of Zhejiang University College of Medicine
Hangzhou, Zhejiang, 310052, China
-
The first hospital of jilin university
Changchun, Jilin, 130021, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.